Zobrazeno 1 - 10
of 126
pro vyhledávání: '"M M, Nau"'
Autor:
Stan Lipkowitz, Seth A. Ettenberg, Mauricio Cuello, Ginger J. Gardner, I Darko, A O Coats, M M Nau, J R Liu, Michael J. Birrer
Publikováno v:
Cell death and differentiation. 11(5)
The majority of ovarian cancer cells are resistant to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Subtoxic concentrations of the semisynthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) enhanced TRAIL-medi
Autor:
M, Cuello, S A, Ettenberg, A S, Clark, M M, Keane, R H, Posner, M M, Nau, P A, Dennis, S, Lipkowitz
Publikováno v:
Cancer research. 61(12)
We investigated whether combined treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and trastuzumab could enhance the specific killing of cells that overexpress the erbB-2 receptor. The combination resulted in an enhanceme
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(9)
Desmoplastic small round cell tumor (DSRCT) is a primitive sarcoma with a consistent cytogenetic abnormality, t(11;22)(p13;q12). This chromosomal translocation generates a chimeric transcript that is formed by fusion of the 5' region of the Ewing's s
Publikováno v:
Cancer research. 59(3)
Expression and function of the TRAIL apoptotic pathway was investigated in normal and malignant breast epithelial cells. Glutathione-S-transferase (GST)-TRAIL extracellular domain fusion proteins were produced to analyze TRAIL-induced apoptosis. Only
Autor:
C A, Felix, R, Wasserman, B J, Lange, D L, Brown, M M, Nau, D E, Cole, J D, Minna, D G, Poplack
Publikováno v:
Leukemia. 8(6)
Based upon in vitro evidence of p53 involvement in lymphoid differentiation, we assessed immunoglobulin (Ig) and T-cell receptor (TCR) genes in five acute lymphoblastic leukemias (ALLs) with, and 24 ALLs without p53 mutations to compare their genotyp
Autor:
O I, Olopade, D L, Buchhagen, K, Malik, J, Sherman, T, Nobori, S, Bader, M M, Nau, A F, Gazdar, J D, Minna, M O, Diaz
Publikováno v:
Cancer research. 53
Cytogenetic analyses of non-small cell lung cancer have revealed deletions of the short arm of chromosome 9 with breakpoints at 9p11-pter in a significant proportion of tumors. Recent evidence suggests that homozygous loss of the interferon (IFN) and
Autor:
C A, Felix, E A, Strauss, D, D'Amico, M, Tsokos, S, Winter, T, Mitsudomi, M M, Nau, D L, Brown, A M, Leahey, M E, Horowitz
Publikováno v:
Oncogene. 8(5)
A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heteroz
Autor:
C A, Felix, C C, Kappel, T, Mitsudomi, M M, Nau, M, Tsokos, G D, Crouch, P D, Nisen, N J, Winick, L J, Helman
Publikováno v:
Cancer research. 52(8)
The p53 gene was examined in primary or metastatic tumors from six patients with rhabdomyosarcoma (RMS) and in five RMS cell lines by screening methods including single-strand conformation polymorphism analysis, the RNase protection assay, sequencing
Autor:
S M, Bodner, J D, Minna, S M, Jensen, D, D'Amico, D, Carbone, T, Mitsudomi, J, Fedorko, D L, Buchhagen, M M, Nau, A F, Gazdar
Publikováno v:
Oncogene. 7(4)
We investigated the immunocytochemical staining and immunoblotting characteristics of 33 different p53 mutant proteins identified in lung cancer cell lines (18 small-cell lung cancer and 15 non-small-cell lung cancer) using monoclonal antibodies pAbs
Autor:
T, Mitsudomi, S M, Steinberg, M M, Nau, D, Carbone, D, D'Amico, S, Bodner, H K, Oie, R I, Linnoila, J L, Mulshine, J D, Minna
Publikováno v:
Oncogene. 7(1)
We screened 77 non-small-cell lung cancer (NSCLC) cell lines for mutations of the p53 gene using a single-strand conformation polymorphism (SSCP) assay. We found that 57 cell lines (74%) had mutations of the p53 gene. Three cell lines had a deletion